Drug
Redasemtide
Redasemtide: highest development phase Phase 2, developed by Shionogi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Shionogi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Redasemtide NCT05953480 | Phase 2 | Acute Ischemic Stroke |
Latest
No recent events.
Follow Redasemtide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.